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What’s new? 
 There are few evidence-based models of diabetes care that include mental health and 
social care. 
 The Three Dimensions for Diabetes (3DFD) model integrated social care, mental 
health and diabetes care into one service. 
 This non-randomized, observational study, set in three diverse boroughs in London, 
UK, recruited adults with suboptimal glycaemic control and mental health and/or 
social problems. 
 3DFD was associated with clinically significant reductions in glycaemic control but 
because they were already a very expensive and high-risk group, there was no 
evidence of reduction in costs compared with the control. 
 
Abstract 
Aims We examined the effectiveness of a service innovation, Three Dimensions for Diabetes (3DFD), 
that consisted of a referral to an integrated mental health, social care and diabetes treatment 
model, compared with usual care in improving biomedical and health economic outcomes. 
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Methods Using a non-randomized control design, the 3DFD model was offered in two inner-city 
boroughs in London, UK, where diabetes health professionals could refer adult residents with 
diabetes, suboptimal glycaemic control [HbA1c ≥ 75 mmol/mol (≥ 9.0%)] and mental health and/or 
social problems. In the usual care group, there was no referral pathway and anonymized data on 
individuals with HbA1c ≥ 75 mmol/mol (≥ 9.0%) were collected from primary care records. Change in 
HbA1c from baseline to 12 months was the primary outcome, and change in healthcare costs and 
biomedical variables were secondary outcomes. 
 
Results 3DFD participants had worse glycaemic control and higher healthcare costs than control 
participants at baseline. 3DFD participants had greater improvement in glycaemic control compared 
with control participants [−14 mmol/mol (−1.3%) vs. −6 mmol/mol (−0.6%) respectively, P < 0.001], 
adjusted for confounding. Total follow-up healthcare costs remained higher in the 3DFD group 
compared with the control group (mean difference £1715, 95% confidence intervals 591 to 2811), 
adjusted for confounding. The incremental cost-effectiveness ratio was £398 per mmol/mol unit 
decrease in HbA1c, indicating the 3DFD intervention was more effective and costed more than usual 
care. 
 
Conclusions A biomedical, psychological and social criteria-based referral system for identifying and 
managing high-cost and high-risk individuals with poor glycaemic control can lead to improved 
health in all three dimensions. 
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<H1>Introduction 
In the UK, around 4 million people have diabetes, costing almost £10 billion/year in direct costs 
alone, 80% of which is for complications [1]. Psychiatric morbidity, diabetes-related distress and 
social problems (e.g. debt, unemployment, isolation and poor housing) are common barriers to 
diabetes self-care and are associated with reduced self-management, which leads to suboptimal 
glycaemic control, increased risk of diabetes complications, premature mortality and increased 
healthcare costs [2–8]. National guidance recognizes that integrating social and psychological care 
with medical care could lead to better health outcomes [9]. 
Integrating the treatment of depression with diabetes care improves outcomes for both conditions 
and reduces costs [10,11], but studies that have attempted to integrate social welfare are almost 
non-existent. The highest prevalence rates of diabetes and the worst diabetes outcomes occur in 
inner-city settings [12,13]. Although there have been several interventions to intensify medical and 
educational interventions in inner-city settings to improve self-management and glycaemic control, 
there have been no interventions that address social problems with the aim of improving glycaemic 
control [14,15]. We found in a feasibility pre–post observational study design that integrating 
diabetes, mental health and social care into one service, the Three Dimensions For Diabetes (3DFD) 
model, was associated with improvements in biomedical, mental health, social and cost outcomes 
[16]. 
The primary aim of this pilot study was to further test whether 3DFD was associated with greater 
change in glycaemic control, other diabetes-related biomedical outcomes, and in healthcare costs 
compared with a control group receiving usual care over 12 months. Our secondary aim was to 
assess the change in psychological and subjective measures of healthcare use in the 3DFD group only 
from referral to 12-month follow-up. 
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<H1>Material and methods 
<H2>Design 
We used a non-randomized control design in which we compared individuals who were referred to 
3DFD with a contemporaneous control group receiving usual care [17]. The rationale for a non-
randomized design was that the funding body had requested a control group but not a randomized 
controlled trial (RCT) as the results were to inform the commissioners as to whether there was any 
clinical and economic evidence to translate this model into routine care. 
 
<H2>Setting 
3DFD was set in Lambeth and Southwark, London, UK, which are adjacent inner-city boroughs with 
populations of 324 431 and 308 401 persons, and with high levels of ethnic diversity and significant 
socio-economic deprivation, as measured by the English Indices of Multiple Deprivation (IMD) 2010 
[18]. The contemporaneous control group was set in Lewisham, a neighbouring borough with 
275 900 residents and similar levels of ethnic diversity and deprivation. This borough did not have 
the 3DFD service or any diabetes-specific mental health or social care services, but shared the same 
diabetes clinical pathways as Lambeth and Southwark, and therefore had a comparable healthcare 
profile [19]. We invited all primary care practices in Lewisham to participate. The study was granted 
ethical approval by the East Kent Research Ethic Committee (Reference 13/LO/0101; NHS Research 
& Development number RJ113/N306) to collect data after informed consent for the 3DFD group and 
for the control group general practices to screen their registers for eligible individuals and generate 
anonymized diabetes-related data. 
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<H2>Participant selection 
For the 3DFD group, we used a referral form with the following criteria of: (1) HbA1c ≥ 75 mmol/mol 
(≥ 9.0%) and (2) the presence of psychiatric morbidity (including depression, psychosis, eating or 
anxiety disorder, substance misuse or diabetes adherence problems) and/or social problems 
(housing, debt, literacy problems, unemployment) as diagnosed and judged by the referring clinician 
as contributing to reduced self-management. We excluded individuals who were already registered 
under mental health services, because 3DFD aimed to identify participants with unmet or previously 
unidentified mental health or social needs or who did not meet the clinical criteria for mental health 
services. We did not distinguish between types of diabetes. Participants could be referred from any 
point on the care pathway from primary to secondary care [19]. 
For the control group, consenting practices collected sociodemographic and biomedical data from 
their electronic medical records to identify individuals who met the first 3DFD referral criterion, 
which was having a current HbA1c ≥ 75 mmol/mol (≥ 9.0%). 
 
<H2>Interventions 
<H3>Usual care 
This consisted typically of a diabetes multidisciplinary team (MDT), which included a general 
practitioner (GP), diabetologist, diabetes specialist nurse and dietitian in three settings of increasing 
severity: primary, intermediate and secondary care. The pathway in all three boroughs was aligned 
with the principles of the Diabetes Guide for London [19] in which there was no provision for mental 
health or social care. 
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<H3>3DFD intervention 
The 3DFD team consisted of a full-time consultant liaison psychiatrist and two full-time 
community support workers from a third-sector (or non-governmental organization), 
voluntary organization, Thames Reach, that provided social welfare. Thames Reach helps 
homeless and vulnerable people to be rehoused and rebuild their lives (thamesreach.org.uk). This 
combination of specialists was selected based on our pilot study [16] which observed higher levels of 
severe psychiatric morbidity. The psychiatrist was also trained to deliver brief psychological 
therapies. 
From 1 October 2012 to 30 September  2013, any professional from the diabetes MDT in Lambeth 
and Southwark (i.e. a GP, diabetologist, diabetes specialist nurse or dietitian) could refer adult 
individuals to 3DFD via a standardized online or paper referral form. Each referral was discussed and 
triaged at weekly 3DFD team meetings attended by the psychiatrist and community worker and 
allocated to: (1) the liaison psychiatrist (if the referral indicated pressing safety concerns or presence 
of multiple psychiatric morbidities) for a diagnostic assessment and initiation and monitoring of 
psychotropics; (2) assessment for psychological therapy; and/or (3) the community support worker if 
social problems were recorded. All individuals who were referred and met the criteria were included 
as participants. The 3DFD clinics were integrated into diabetes teams and clinics and the third-
sector support workers delivered outreach work from their offices or participants’ homes. The final 
follow-up took place on 17 June 2015. 
Following a clinical psychiatric assessment using the International Classification of Disorders-10 (ICD-
10) criteria for psychiatric disorders [20] and identifying the barriers to optimal diabetes control, the 
treatment options consisted of: diabetes-focused cognitive behaviour therapy (CBT) [21]; initiation 
and monitoring of psychotropics; and/or social interventions, which involved advocacy in housing, 
debt problems, childcare, domestic violence, immigration and/or signposting to employment 
training. These were integrated into their routine diabetes care by ensuring 3DFD clinics were co-
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located with the diabetes MDT clinics via joint consultations with the key diabetes healthcare 
professionals or weekly feedback at the generic diabetes MDT meetings. The 3DFD liaison 
psychiatrist and/or community worker met the participant in weekly-to-monthly appointments, 
depending on their needs, for a period of up to 6 months. Separate weekly 3DFD MDT meetings 
provided an opportunity to discuss challenges in treatment and for supervision. Discharge into 
routine diabetes care was planned with the generic diabetes MDT. 
 
<H2>Measures 
At baseline and 12 months for all participants, we collected the following data from medical records: 
sociodemographic variables (age, gender, self-reported ethnicity, postcode for IMD 2010 score and 
decile), biomedical variables [HbA1c, serum cholesterol, eGFR, albumin-to-creatinine ratio (ACR), BMI 
and BP], macrovascular and microvascular complications, and prescribed medications. 
For both groups, the primary outcome was change in HbA1c from baseline (time of referral for 3DFD 
group) to 12-month follow-up (i.e. 6 months after discharge from the 3DFD intervention). Secondary 
outcomes were the remaining biomedical outcomes (serum cholesterol, eGFR, ACR, BMI and BP). 
Service use was coded and costed as number of emergency department (ED) visits, inpatient 
admissions and outpatient visits, length of inpatient bed stays, and number of outpatient 
appointments offered and attended in the previous 12 months at baseline and follow-up. We 
calculated the cost of the intervention as £209 785.50, based on the salaries of one psychiatrist 
(£76 761/year), and one senior (£32 802/year) and one junior (£30 294/year) Thames Reach worker 
for the duration of the intervention’s implementation (18 months). 
We could collect self-report psychological, social and service use measures at baseline and 12 
months in the 3DFD group only. These included: the Patient Health Questionnaire (PHQ-9), a nine-
item questionnaire that screens for severity and number of depressive symptoms (range 0–27) with 
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a score of  10 representing case threshold for likely depressive disorder [22]; the Generalized 
Anxiety Disorder-7 (GAD-7) scale, a seven-item questionnaire for screening for the presence and 
severity of anxiety (range 0–21), with scores ≥ 10 indicating possible anxiety disorder [23]; and the 
Diabetes Distress Scale (DDS), a 17-item instrument for the assessment of diabetes-related 
emotional distress with a score of  40 representing clinical significance [24]. For social functioning, 
we used the Independent Living Star™, a multidisciplinary tool originating in the third-sector which 
has been since adapted and validated for measuring the outcomes of social and psychological 
interventions [25]. Participants rate eight areas of social functioning on a Likert scale, where higher 
scores indicate higher levels of functioning: (1) Where you live, (2) Looking after yourself, (3) Health, 
(4) Being treated with dignity, (5) Meaningful activity, (6) Social life, (7) Managing money, and (8) 
How you feel. 
 
<H2>Power calculation 
The power calculation was informed by the effect size observed in the earlier study [16], however, 
we anticipated a more conservative between-group difference. We estimated that the improvement 
in HbA1c in the 3DFD group would be 4 mmol/mol greater than the control group (with a pooled 
standard deviation of 15 mmol/mol), corresponding to a small effect size of 0.25 (Cohen’s d). At a 
power of 80% and two-sided significance level of 0.05, a per group sample size of 252 was required 
for comparing two means. 
 
<H2>Statistical analysis 
We included 3DFD participants who were accepted into the intervention and controls that were 
identified anonymously. We described the baseline characteristics as means (SD) for continuous 
variables and as counts (%) for categorical variables. Baseline characteristics of each group were 
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compared using Student’s t-test or χ2 test for continuous and categorial variables respectively. We 
compared the change in biomedical outcomes from baseline to 12 months between groups with t-
tests. For the self-report measures collected in the 3DFD group only, paired t-tests were used to 
investigate changes from baseline to follow-up. Distributions of continuous variables were checked 
with histograms and QQ plots; skewed variables were analysed with non-parametric tests (i.e. 
Mann–Whitney U-test). We used Fisher’s exact test for comparing IMD 2010 quintiles as some cells 
contained zero or almost zero observations. 
Using linear regression models, our primary analyses compared the change in HbA1c and the other 
biomedical outcomes in the 3DFD vs. control group. We adjusted for relevant potential confounders 
(age, gender, ethnicity, IMD 2010 score, type of diabetes and diabetes duration). Residual plots were 
visually checked to see if the regression models fit the data and if any assumptions were violated. 
We recorded health service use (inpatient admissions, ED visits and outpatient clinic attendance) 
and calculated costs by estimating the cost per contact with the service based on staff and other 
expenditure data, overheads and activity levels. Other service costs were calculated by combining 
the data collected from hospital and primary care records with appropriate unit cost information 
[26]. 
For our economic analysis, we compared total follow-up healthcare costs between groups in a 
regression model, adjusting additionally for baseline costs and change in HbA1c. We used a 
bootstrapped model with 1000 replicates, which makes no assumptions about the underlying data 
distribution, to estimate the 95% confidence intervals (95% CI) of coefficients, as regression analyses 
of cost data often result in non-normally distributed residuals [27]. We did not transform the data as 
this would distort the true spread of morbidity and costs. For 3DFD participants only, total follow-up 
costs included the per-participant cost of the intervention. 
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The incremental cost-effectiveness ratio (ICER) was calculated for the ratio of follow-up total costs to 
HbA1c, adjusting for baseline values, as follows: (cost3DFD – costcontrol)/(HbA1c3DFD – HbA1ccontrol). The 
ICER was bootstrapped with 1000 replicates, its 95% CI calculated, and uncertainty around the 
estimate was shown by plotting the replicates on the cost-effectiveness plane. 
We performed a per-protocol sensitivity analysis as well because a small group of participants were 
recruited with HbA1c < 75 mmol/mol (< 9.0%), as they had serious psychiatric and/or social 
problems. The above primary and cost analyses were redone excluding these participants. 
 
<H3>Propensity score analyses 
In addition to the regression analyses, we conducted a propensity score analysis (PSA) with 
stratification to investigate the effect of the 3DFD intervention on change in HbA1c and total follow-
up healthcare costs to reduce the potential bias in our estimation of the treatment effect due to the 
observational and non-randomized design. A PSA allows for the balancing of measured covariates 
between the control and treatment groups in an observational study [28]. An advantage of the PSA 
over multiple regression is that by matching by propensity scores we do not rely on the linearity 
assumptions between confounders and outcome as in multiple regression. However, PSA does not 
allow extrapolation and we may not be able to make inferences about certain groups. 
Participants with complete data on the relevant variables were used for the PSA. Propensity scores 
for change in HbA1c and healthcare costs were calculated by predicting treatment group status from 
five (age, gender, ethnicity, 2010 IMD score and baseline HbA1c) and eight variables (additionally 
complications, type of diabetes and baseline total costs) respectively, in a logistic regression model. 
Participants were then stratified based on quintiles of the propensity scores to create five, relatively 
equal-sized groups. Treatment effects on change in HbA1c and costs were estimated within each 
stratum and pooled across strata. We checked the balancing of covariates. 
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Data were analysed using SPSS for Windows (version 22) and, for the PSA and bootstrapped cost 
statistics, R (version 3.4.1). 
 
<H2>Participant involvement 
Thinkpublic, a social enterprise that supports qualitative research co-design projects in the 
community, conducted semi-structured interviews with participants after our pilot study to inform 
the content of the intervention for this project. They asked for participant feedback as to the key 
facilitators for improving their care and suggested improvements (report available from the authors) 
[16,29]. 
 
<H1>Results 
<H2>Comparison of 3DFD and control groups 
During the study period, we received 307 referrals of which 277 individuals met the 3DFD criteria. In 
the control group, the five largest general practices in Lewisham agreed to participate and 292 
individuals were anonymously identified from the diabetes registers who met the first eligible 
criterion of HbA1c ≥ 75 mmol/mol (≥ 9.0%) (Fig. 1). 
Table 1 presents baseline characteristics. The 3DFD group overall had greater morbidity and greater 
risk of diabetes complications. On average they were 10 years younger, more likely to be female or 
from an ethnic minority, and slightly less likely to be living in the most deprived areas. The 3DFD 
group had poorer glycaemic control, longer duration of diabetes and a higher proportion of 
participants with Type 1 diabetes. In addition, the 3DFD group had more Type 2 diabetes 
participants receiving current insulin therapy. The 3DFD group also had higher mean eGFR values but 
a lower mean BMI. 
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In the 3DFD group, 47 (17.0%) participants were offered all three dimensions of care (prescribed 
psychotropic medication, CBT, and social support). Seventeen (6.1%) participants were prescribed 
medication and offered social support, and 77 (27.8%) were offered CBT and social support. Ten 
(3.6%) participants were offered CBT only and 48 (17.3%) were offered social support only. Seventy-
eight (28.2%) did not receive any of the 3DFD services. 
Table S1 presents the unadjusted between-group difference in change in biomedical outcomes from 
baseline to 12 months; the mean reduction in glycaemic control in the 3DFD group was significantly 
greater than in the control group, with no other differences observed for the other biomedical 
outcomes. 
 
<H3>Primary analyses 
In the multivariate analysis adjusting for potential confounders, the change in HbA1c was significantly 
greater in the 3DFD group compared with the control group (Table 2). Additionally, we observed 
that the 3DFD group had greater decreases in ACR values over time. Residual plots indicated that the 
models fit the data well. Low adjusted-R2 values for the biomedical outcomes suggest that treatment 
status and the covariates explained very little of these variables’ variance. 
<H3>Economic analyses 
Table 3 reports health service use and costs by group at baseline and follow-up. The mean baseline 
total costs were about three times higher in the 3DFD group than the control group. In both groups, 
the costs of diabetes care had increased; although the rate of increase in the 3DFD group appeared 
less than in the control group, the difference between the two groups remained significant at follow-
up. In the multivariate analysis, total follow-up costs were significantly greater in the 3DFD group 
than in the control group (Table 2). 
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After adjusting for baseline values, the between-group differences in total follow-up costs and 
follow-up HbA1c values were £1988 and 5 mmol/mol (0.6%) respectively, yielding an ICER of £398 
per mmol/mol unit decrease in HbA1c. In other words, every 10 mmol/mol (1.1%) decrease in HbA1c 
costs £3980 in additional healthcare use, including the cost of the 3DFD intervention over 12 
months, compared with usual care. The bootstrapped results almost entirely fell within the north-
east quadrant of the plane (Fig. S1), strongly suggesting that the 3DFD intervention was more 
expensive and more effective. 
 
<H3>Sensitivity analyses 
For the per-protocol analyses, 58 participants were excluded for having a baseline HbA1c 
< 75 mmol/mol (<9.0%), leaving 240 (37 excluded) participants in the 3DFD group and 274 (18 
excluded) in the control group remaining. The baseline characteristics of each group were similar to 
those in the original sample. The results closely resembled the above results, namely that, compared 
with the control group, the 3DFD group from baseline to follow-up had a significantly greater 
reduction in HbA1c, no statistically different changes in other biomedical variables, greater 
healthcare costs in absolute units, and statistically significant improvements in the psychological and 
social measures. The results of the sensitivity analyses are not shown but the data are available upon 
request. 
 
<H3>PSA 
There were 452 participants (3DFD group n = 203, 44.9%) with complete data on the variables for 
the PSA. Five strata were created, with sizes of 90 or 91 participants each, and a minimum of 20% 
participants from one group in each stratum. In the lowest, second and fourth strata, 3DFD 
participants had significantly greater decreases in HbA1c (Table S2). When pooling across strata, the 
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3DFD treatment effect was also significant. When checking the balance diagnostics of the covariates, 
some group differences remained within strata: age (higher in control group in the top stratum), 
baseline HbA1c (higher in control group in the third stratum), IMD 2010 score (higher in 3DFD group 
in the third stratum). 
For the PSA comparing follow-up total healthcare costs, 556 participants across the two groups 
(3DFD group n = 270, 48.6%) with complete data on the relevant variables were included. Five strata 
were created, of 111–112 participants each, and a minimum of 16% participants from one group in 
each stratum. Within each and across all strata, follow-up costs were not different between groups 
(pooled estimate £212, 95% CI −302 to 727). 
 
<H2>3DFD group only 
On the self-report measures, 3DFD participants indicated experiencing high levels of psychological 
difficulties (Table S3). In the pre–post analysis in the 3DFD group, there were statistically significant 
improvements in each psychological and social outcome (Table S3). 
<H1>Discussion 
This study tested the potential effectiveness of a service that integrated mental health and social 
care into the diabetes care pathway. We found that individuals actively being identified by diabetes 
health providers referred into to the 3DFD service were at higher risk of diabetes complications and 
costing the health system three times more than using the HbA1c cut-off of 75 mmol/mol (9.0%) 
alone as in the control group. We also found that the integrated 3DFD service was effective, but not 
cost-effective, in reducing glycaemic control after adjusting for baseline potential confounders 
compared with the control group. We also found in the 3DFD group only that measures of 
psychological and social functioning improved. 
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<H2>Strengths 
We used a study design that allowed us to model a service innovation at a cluster level in the real-
world setting of an inner-city with very high levels of socio-economic deprivation. The criteria were 
broad and simple to be inclusive to all types of mental health and/or social problems and to ensure 
that they were user-friendly by busy clinician referrers. This contrasts with other models of 
integrated care that focused only on depression in diabetes, thus limiting the generalizability of their 
findings to one comorbidity [10,11]. We also achieved high follow-up rates for our primary outcome, 
HbA1c. 
 
<H2>Limitations 
The main limitation is the non-randomized design. An RCT was not appropriate as the service 
innovation was funded in only two boroughs. As an unexpected consequence, due to the non-
randomized design, having a referral system in the intervention group led to recruitment of 
participants who were sicker than the control group; they had worse glycaemic control, were 
younger, more likely to have Type 1 diabetes and at greater risk of health disparities. Although we 
did not have psychiatric or social data for the control group, we appear to have selected a less sick 
group and we thus likely underestimated the cost-effectiveness of the intervention. For the 3DFD 
group, having a referral system that explicitly includes a mental health or social problems appears to 
encourage health professionals to select individuals for whom they had more concerns. 
Second, we had a smaller number of practices agreeing to participate in the control borough and 
their diabetes population may have had better health status. We adjusted for the baseline 
differences between the 3DFD and control group in the multivariate analysis and used a PSA, and the 
effect of the 3DFD intervention on glycaemic control remained significant. A further limitation is that 
many 3DFD participants were missing outcome data on psychological measures at 12-month follow-
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up because these data were being collected as participants presented routinely, potentially biasing 
our findings towards positive effects on mental health. Another limitation is that the inner-London 
setting is potentially different from other inner-city settings across the UK, for instance, in its ethnic 
and socio-economic diversity. We were not able to adjust for some potential confounders such as 
marital status. Finally, we conducted several statistical analyses with a relatively small sample size, 
thus some of our findings may be false positives. Overall, our findings are to be interpreted with 
caution and need further validation. 
 
<H2>Interpretation 
Although there have been many clinical trials of treating depression and diabetes distress in people 
with diabetes [10,30–32], there is almost no published literature evaluating the benefits on 
biomedical, psychological and social outcomes of integrating mental health and social care into a 
diabetes service [30]. The cost of diabetes is greater for those who are diagnosed earlier and 
therefore have a longer duration [33]. We observed this in our 3DFD group where costs before 
treatment were three times higher. The control group shows that the annual cost of diabetes 
increases rapidly and the 3DFD intervention suggests that it can slow down this inevitable year-on-
year increase in costs. 
The cost of 3DFD was £757.35 per person over 12 months and was associated with a reduction of 
10 mmol/mol (1.1%) in HbA1c. This is favourable compared with adding a second or third diabetes 
drug, for instance, adding liraglutide 1.8 mg/day for 12 months would cost the NHS an additional 
£1433.24 per person [34]. However, as well as knowing the cost of pharmacological interventions, 
we would also need to establish their effectiveness in comparison with 3DFD because healthcare 
decisions cannot be made on the basis of cost alone. 
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The added value of integrating mental health and social care into patient management seems to 
result in multidimensional improvements in outcomes and of a larger magnitude than those 
observed in clinical trials of collaborative care [35]. Referral processes and pathways of care that 
include an assessment of mental health and social problems encourage clinicians to identify a group 
of much higher risk individuals, rather than using poor glycaemic control alone as an indicator of 
psychological or social distress or greater healthcare utilization. Another added value is that 3DFD 
crossed organizational boundaries from primary care to specialist diabetes services, overcoming 
many communication barriers. There are very few similar models to compare with 3DFD. The Rapid, 
Assessment, Interface and Discharge (RAID) model is a specialist multidisciplinary mental health 
service for rapid discharge of mentally ill individuals presenting in ED settings and was associated 
with significant cost savings, and despite lacking the RCT gold-standard evidence, has been widely 
disseminated [36]. A recent pragmatic cluster RCT of integrated psychological and biomedical 
approach to multi-morbidity in primary care did not lead to improved quality of life, possibly 
because social factors were not included [37]. Our findings suggest there is now a need for a cluster 
RCT to test the effectiveness and cost-effectiveness of integrated psychiatric and social care in 
diabetes services. 
 
<H1>Conclusions 
In summary, a biomedical, psychological and social criteria-based referral system for 
identifying and managing high-cost and high-risk individuals with poor glycaemic control 
can lead to improved health in all three dimensions. The cost of the intervention was lower 
than second-line diabetes drugs. 
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Table 1 Baseline characteristics of 3DFD and control participants 
Baseline characteristics 
3DFD 
(n = 277)*
 
Control 
(n = 292)† 
P-value 
Age, years (SD) 46.8 (15.0) 57.2 (14.2) < 0.001 
Gender, female 168 (60.7) 137 (47.7) 0.003 
Ethnicity White 114 (41.2) 150 (51.4) 
0.003 African/Caribbean 127 (45.) 93 (31.9) 
Asian/Mixed/Other 36 (13.0%) 49 (16.8) 
IMD 2010 
quintile‡ (%)
 
1, least deprived 2 (0.7) 0 
< 0.001 
2 6 (2.2) 0 
3 22 (8.0) 48 (16.4) 
4 147 (53.3) 108 (37.0) 
5, most deprived 99 (35.9) 136 (46.6) 
Type of 
diabetes  
Type 1 90 (32.5) 23 (8.0) 
< 0.001 
Type 2 187 (67.5) 264 (92.0) 
Duration of diabetes, years (SD) 11.4 (8.8) 9.4 (7.3) 0.015§
 
Current insulin therapy 183 (66.3) 119 (40.8) < 0.001 
HbA1c, mmol/mol (SD) 97 (21) 93 (17) 
0.013 
HbA1c, % (SD) 11.0 (1.9) 10.7 (1.6) 
Serum cholesterol, mmol/l (SD) 4.77 (1.33) 4.69 (1.23) 0.53 
eGFR, ml min
−1
 1.73m
−2
 (SD) 80.2 (25.6) 74.6 (15.5) 0.007 
ACR, mg/mmol  (SD) 8.4 (17.5) 10.8 (37.9) 0.30§
 
BMI, kg/m
2
 (SD) 30.0 (7.7) 31.5 (6.4) 0.032 
BP systolic, mmHg (SD) 130.3 (18.7) 132.4 (15.8) 0.21 
BP diastolic, mmHg (SD) 77.4 (10.1) 78.9 (9.7) 0.12 
Macrovascular 
complications 
None 87 (43.3) 112 (41.0) 
0.69 
At least one 114 (56.7) 161 (59.0) 
Microvascular 
complications  
None 66 (32.2) 80 (30.4) 
0.76 
At least one 139 (67.8) 183 (69.6) 
Data are mean (SD) or n (%), as appropriate. Percentages were calculated after the missing data for the 
respective variable were excluded. 
Values in bold are statistically significant. 
*Number of missing cases for the 3DFD group is: gender, 5; IMD quintile, 1; type of diabetes, 5; macrovascular 
complications, 76; microvascular complications, 72. 
†Number of missing cases for the control group is: gender, 5; type of diabetes, 5; macrovascular 
complications, 19; microvascular complications, 29. 
‡IMD quintiles were derived from the national deciles (i.e. deciles 1 and 2 were collapsed to form quintile 1). 
§Diabetes duration and albumin-to-creatinine ratio values were skewed and non-parametric tests were used. 
IMD, Index of Multiple Deprivation; ACR, albumin-to-creatinine ratio. 
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Table 2 Results of the regression analyses predicting change in HbA1c and other biomedical outcomes and total follow-up healthcare costs 
 
HbA1c 
(mmol/mol) 
Serum 
cholesterol 
(mmol/L) 
eGFR 
(ml min
−1
 1.73m
−2
) 
ACR (mg/mmol) BMI (kg/m
2
) 
BP systolic 
(mmHg) 
BP diastolic 
(mmHg) 
Total follow-up 
costs (£) 
Model coefficients 
Estimate (95% 
CI) 
Estimate (95% CI) Estimate (95% CI) 
Estimate (95% 
CI) 
Estimate 
(95% CI) 
Estimate 
(95% CI) 
Estimate 
(95% CI) 
Estimate (95% 
CI)*
 
Treatment group 
(control vs. 3DFD) 
−10.5 (−15.2 to 
−5.8) 
−0.11 (−0.54 to 
0.32) 
0.66 (−2.67 to 3.99) 
−12.08 (−22.24 
to −1.93) 
−0.04 (−0.63 
to 0.56) 
0.29 (−3.88 to 
4.47) 
0.53 (−1.91 
to 2.96) 
1336.65 (242 to 
2351) 
Age (years) 
−0.4 (−0.6 to 
−0.2) 
0 (−0.01 to 0.02) −0.11 (−0.24 to 0.02) 
−0.14 (−0.51 to 
0.24) 
0.01 (−0.01 
to 0.03) 
0.04 (−0.12 to 
0.19) 
−0.03 (−0.12 
to 0.06) 
−5.62 (−43.82 to 
32.16) 
Gender (male vs. 
female) 
−0.4 (−4.7 to 
4.0) 
−0.39 (−0.78 to 
−0.01) 
−1.99 (−4.96 to 0.98) 
3.72 (−4.74 to 
12.17) 
−0.07 (−0.61 
to 0.47) 
−2.39 (−6.17 
to 1.39) 
1.03 (−1.18 
to 3.23) 
−521.48 
(−1382.2 to 
525.3) 
Ethnicity (white vs. 
black) 
1.5 (−3.3 to 
6.4) 
−0.05 (−0.48 to 
0.37) 
−0.16 (−3.47 to 3.15) 
−0.84 (−10.21 to 
8.53) 
0.09 (−0.51 
to 0.69) 
−0.13 (−4.34 
to 4.09) 
−0.8 (−3.26 
to 1.66) 
−1532.02 
(−2664 to −492) 
Ethnicity (white vs. 
other) 
7.2 (1.2 to 
13.3) 
0.1 (−0.46 to 
0.67) 
−0.19 (−4.51 to 4.14) 
2.34 (−9.51 to 
14.18) 
0.42 (−0.33 
to 1.18) 
0.62 (−4.65 to 
5.89) 
−0.42 (−3.51 
to 2.67) 
−1153.53 
(−2252 to −163) 
Type of diabetes 
(Type 1 vs. Type 2) 
6.1 (−1.2 to 
13.4) 
−0.33 (−1 to 0.33) 1.21 (−4.12 to 6.54) 
−17.69 (−33.29 
to −2.09) 
−0.47 (−1.42 
to 0.48) 
−0.21 (−6.74 
to 6.32) 
1.71 (−2.11 
to 5.53) 
−1451.17 
(−2963 to 657)   
IMD 2010 score 
0.1 (−0.3 to 
0.4) 
0.01 (−0.02 to 
0.04) 
0.01 (−0.22 to 0.23) 
0.08 (−0.57 to 
0.73) 
0 (−0.04 to 
0.04) 
0.01 (−0.27 to 
0.3) 
−0.02 (−0.19 
to 0.14) 
−6.07 (−60.34 to 
46.47) 
Diabetes duration 
(years) 
0.5 (0.2 to 0.8) 
0.01 (−0.02 to 
0.03) 
0.01 (−0.2 to 0.21) 
0.19 (−0.42 to 
0.79) 
0.01 (−0.03 
to 0.05) 
−0.31 (−0.57 
to −0.06) 
−0.1 (−0.25 
to 0.05) 
27.03 (−38.75 to 
83.31) 
Change in HbA1c 
(mmol/mol) 
       
−11.47 (−31.78 
to 8.53) 
Total baseline costs 
(£) 
       
0.39 (0.27 to 
0.94) 
Model statistics 
 
       
Adjusted R
2
 0.06 0.00 −0.01 0.02 −0.01 0.00 −0.01 0.33 
For HbA1c and other biomedical outcomes, negative coefficient estimates indicate decreases in that variable from baseline to 12-month follow-up. 
Values in bold are statistically significant. 
Intercept terms were included in each model but are not reported here. IMD 2010 scores were entered as a continuous variable. 
*Bootstrapped percentile 95% confidence intervals (CI) are presented. 
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Table 3 Healthcare use and costs per participant in the preceding 12 months from baseline and from 12-month follow-up in the 3DFD vs. control group 
 3DFD Control Mean 
difference 
in costs 
(95% CI)†
 
P-value‡
  No. of 
participants 
(%) 
No. of 
visits/leng
th of stay 
Cost (£) 
No. of 
participants 
(%) 
No. of 
visits/lengt
h of stay 
Cost (£) 
Baseline 
Inpatient 
admissions 
100 (36.1) 
2.33 
(2.14) 
2324 
(11 875) 
39 (13.4) 
5.79 
(26.53) 
652 
(3645) 
−1672 
(−3137 to 
−207) 
< 0.001 
ED 
attendance 
118 (42.6) 
2.89 
(3.40) 
150 (316) 65 (22.3) 1.60 (1.73) 
43 
(122) 
−107 (−147 
to −68) 
< 0.001 
Outpatient 
clinic 
attendance 
223 (80.5) 
9.92 
(10.66) 
1012 
(1555) 
228 (78.1) 4.18 (3.92) 
370 
(466) 
−642 (−833 
to −450) 
< 0.001 
Total   
3486 
(12 253) 
  
1065 
(3870) 
−2421 
(−3936 to 
−905) 
< 0.001 
 
Follow-up 
  
Inpatient 
admissions 
103 (37.2) 
3.06 
(2.66) 
2,365 
(7549) 
61 (20.9) 
4.16 
(21.34) 
1025 
(5446) 
−1339 
(−2428 to 
−250) 
< 0.001 
ED 
attendance 
125 (45.1) 
2.52 
(2.78) 
140 (285) 82 (28.1) 1.71 (1.02) 
59 
(116) 
−81 (−117 
to −45) 
< 0.001 
Outpatient 
clinic 
attendance 
238 (85.9) 
11.46 
(11.84) 
1,203 
(1418) 
221 (75.7) 5.44 (5.52) 
487 
(657) 
−716 (−900 
to −532) 
< 0.001 
3DFD 
intervention
* 
  757.35    
  
Total   
4465 
(8214) 
  
1571 
(5760) 
−2893 
(−4068 to 
−1719) 
< 0.001 
Data are mean (SD) or n (%). P-values in bold are statistically significant.  
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No missing data. Length of stay is given in days. 
*Cost of 3DFD intervention per participant is based on total delivery cost of £209 785.50 for 277 participants. 
†3DFD costs are subtracted from control costs. 
‡All variables were heavily skewed and Mann–Whitney U-tests were used to compare groups. 
Ci, confidence intervals; ED, emergency department. 
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